Acuta Capital Partners, LLC Iovance Biotherapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

$70.3 Million
Q4 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $6,833 - $9,399	-717 Reduced 0.46%	153,639 $1.47 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $226,490 - $650,714	35,500 Added 29.87%	154,356 $1.7 Million
Q1 2022 May 16, 2022	SELL	$12.38 - $19.1 $756,900 - $1.17 Million	-61,139 Reduced 33.97%	118,856 $1.98 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $3.22 Million - $5.37 Million	-194,500 Reduced 51.94%	179,995 $3.44 Million
Q3 2021 Nov 15, 2021	BUY	$20.35 - $26.63 $4.58 Million - $5.99 Million	225,000 Added 150.51%	374,495 $9.24 Million
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $847,869 - $1.72 Million	51,921 Added 53.21%	149,495 $3.89 Million
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $1.93 Million - $3.54 Million	-67,226 Reduced 40.79%	97,574 $3.09 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $4.21 Million - $7.55 Million	-150,200 Reduced 47.68%	164,800 $7.65 Million
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $7.63 Million - $9.98 Million	-275,000 Reduced 46.61%	315,000 $10.4 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $5.18 Million - $7.81 Million	190,500 Added 47.68%	590,000 $16.2 Million
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $5.02 Million - $9.98 Million	-257,000 Reduced 39.15%	399,500 $12 Million
Q4 2019 Feb 14, 2020	SELL	$17.95 - $29.41 $1.27 Million - $2.09 Million	-71,000 Reduced 9.76%	656,500 $18.2 Million
Q3 2019 Nov 14, 2019	SELL	$17.99 - $26.0 $30.6 Million - $44.2 Million	-1,699,201 Reduced 70.02%	727,500 $13.2 Million
Q2 2019 Aug 14, 2019	SELL	$9.78 - $24.52 $5.06 Million - $12.7 Million	-517,500 Reduced 17.58%	2,426,701 $59.5 Million
Q1 2019 May 14, 2019	SELL	$8.41 - $11.26 $630,750 - $844,500	-75,000 Reduced 2.48%	2,944,201 $28 Million
Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $5.98 Million - $9.5 Million	796,500 Added 35.83%	3,019,201 $26.7 Million
Q3 2018 Nov 07, 2018	SELL	$11.25 - $17.7 $20.3 Million - $31.9 Million	-1,802,299 Reduced 44.78%	2,222,701 $25 Million
Q2 2018 Aug 15, 2018	SELL	$12.45 - $16.95 $2.93 Million - $3.98 Million	-235,000 Reduced 5.52%	4,025,000 $51.5 Million
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $2.98 Million - $7.18 Million	368,000 Added 9.46%	4,260,000 $72 Million
Q4 2017 Feb 14, 2018	BUY	$6.65 - $9.25 $3.06 Million - $4.26 Million	460,191 Added 13.41%	3,892,000 $31.1 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $15.3 Million - $29.3 Million	3,431,809	3,431,809 $26.6 Million

Others Institutions Holding IOVA

# of Institutions

343

Shares Held

247M

Call Options Held

2.51M

Put Options Held

3.5M

Vanguard Group Inc Valley Forge, PA

27.5M
Shares

$97.5 Million
0.0% of portfolio
Mhr Fund Management LLC New York, NY

24.4M
Shares

$86.4 Million
24.02% of portfolio
Perceptive Advisors LLC New York, NY

22.1M
Shares

$78.3 Million
5.46% of portfolio
Black Rock Inc. New York, NY

21.2M
Shares

$75.1 Million
0.0% of portfolio
State Street Corp Boston, MA

12.2M
Shares

$43.4 Million
0.0% of portfolio

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $559M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.

Account